摘要
目的观察酚妥拉明联合促肝细胞生长素治疗慢性重症肝炎的疗效。方法选择32例慢性重症肝炎患者随机分为治疗组和对照组,治疗组17例,应用酚妥拉明联合促肝细胞生长素等综合治疗,对照组15例,采取促肝细胞生长素等综合治疗,疗程1个月。结果治疗组总胆红素(TBil)降低,凝血酶原活动度(PTA)上升明显,差异显著(P<0.05),治疗组和对照组TBil较治疗前均有明显下降(P<0.01,P<0.05),PTA明显上升(P<0.01)。结论酚妥拉明联合促肝细胞生长素治疗慢性重症肝炎,降低总胆红素、提高凝血酶原活动度,有较好疗效。
Objective To observe the clinical efficacy of Phentolamine - Mesilate combined Hepatocyte growth - promoting factor in the treatment of chronic hepatitis gravis. Methods 32 patients with chronic hepatitis gravis were divided into treated group and control group. Treated group include 17 patients, treated by Phentolamine - Mesilate combined Hepatocyte growth-promoting factor, and control group included 15 patients, treated by Hepatocyte growth-promoting factor. The two groups were given other composite treatment, last 1 month. Results At the end of treatment, serum total bilirubin （Tbil） was lower and prothrombin active（PTA） was higher in treated group compared with control group（ P 〈 0.05 ）. Thil of the two groups were lower （ P 〈 0.01, P 〈 0.05 ）. And PTA were higher （ P 〈 0.01 ） after treatment. Conclusion Phentolamine - Mesilate combined Hepatocyte growth - promoting factor has good clinical efficacy in the treatment of chronic hepatitis gravis.
出处
《菏泽医学专科学校学报》
2007年第3期22-23,共2页
Journal of Heze Medical College
关键词
慢性重症肝炎/治疗
酚妥拉明/治疗应用
促肝细胞生长素/治疗应用
Chronic Hepatitis Gravis/therapy
Phentolamine - MesiLate/therapeutic use
Hepatocyte Growth - Promoting Factor/therapeutic use
